<?xml version='1.0' encoding='utf-8'?>
<document id="24219007"><sentence text="The interaction potential of retigabine (ezogabine) with other antiepileptic drugs."><entity charOffset="29-39" id="DDI-PubMed.24219007.s1.e0" text="retigabine" /><entity charOffset="41-50" id="DDI-PubMed.24219007.s1.e1" text="ezogabine" /><pair ddi="false" e1="DDI-PubMed.24219007.s1.e0" e2="DDI-PubMed.24219007.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24219007.s1.e0" e2="DDI-PubMed.24219007.s1.e1" /></sentence><sentence text="Retigabine is an antiepileptic drug (AED) that reduces neuronal excitability by enhancing neuronal KCNQ (Kv7) potassium channel activity"><entity charOffset="0-10" id="DDI-PubMed.24219007.s2.e0" text="Retigabine" /><entity charOffset="110-119" id="DDI-PubMed.24219007.s2.e1" text="potassium" /><pair ddi="false" e1="DDI-PubMed.24219007.s2.e0" e2="DDI-PubMed.24219007.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24219007.s2.e0" e2="DDI-PubMed.24219007.s2.e1" /></sentence><sentence text="" /><sentence text="This manuscript provides an overview of the drug-drug interaction potential of retigabine with other AEDs, using data collated from both in vitro work and clinical studies, either previously published or from relevant information collated during the development of retigabine"><entity charOffset="79-89" id="DDI-PubMed.24219007.s4.e0" text="retigabine" /><entity charOffset="265-275" id="DDI-PubMed.24219007.s4.e1" text="retigabine" /><pair ddi="false" e1="DDI-PubMed.24219007.s4.e0" e2="DDI-PubMed.24219007.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24219007.s4.e0" e2="DDI-PubMed.24219007.s4.e1" /></sentence><sentence text="" /><sentence text="Retigabine is not a substrate for the major CYP enzymes and at clinically relevant concentrations there is little or no potential for retigabine to inhibit or induce the CYP enzymes or to inhibit the major renal drug transporters"><entity charOffset="0-10" id="DDI-PubMed.24219007.s6.e0" text="Retigabine" /><entity charOffset="134-144" id="DDI-PubMed.24219007.s6.e1" text="retigabine" /><pair ddi="false" e1="DDI-PubMed.24219007.s6.e0" e2="DDI-PubMed.24219007.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24219007.s6.e0" e2="DDI-PubMed.24219007.s6.e1" /></sentence><sentence text=" The addition of retigabine to a range of existing AEDs showed little or no effect on the AED trough concentrations apart from a 20% decrease in lamotrigine concentrations"><entity charOffset="17-27" id="DDI-PubMed.24219007.s7.e0" text="retigabine" /><entity charOffset="145-156" id="DDI-PubMed.24219007.s7.e1" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.24219007.s7.e0" e2="DDI-PubMed.24219007.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24219007.s7.e0" e2="DDI-PubMed.24219007.s7.e1" /></sentence><sentence text=" Results from a small phase II study showed that co-administration of valproic acid and topiramate had no impact on the PK of retigabine whereas carbamazepine and phenytoin increased the clearance of retigabine by approximately 27% and 36%, respectively"><entity charOffset="70-83" id="DDI-PubMed.24219007.s8.e0" text="valproic acid" /><entity charOffset="88-98" id="DDI-PubMed.24219007.s8.e1" text="topiramate" /><entity charOffset="126-136" id="DDI-PubMed.24219007.s8.e2" text="retigabine" /><entity charOffset="145-158" id="DDI-PubMed.24219007.s8.e3" text="carbamazepine" /><entity charOffset="163-172" id="DDI-PubMed.24219007.s8.e4" text="phenytoin" /><entity charOffset="200-210" id="DDI-PubMed.24219007.s8.e5" text="retigabine" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e0" e2="DDI-PubMed.24219007.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e0" e2="DDI-PubMed.24219007.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e0" e2="DDI-PubMed.24219007.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e0" e2="DDI-PubMed.24219007.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e0" e2="DDI-PubMed.24219007.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e0" e2="DDI-PubMed.24219007.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e1" e2="DDI-PubMed.24219007.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e1" e2="DDI-PubMed.24219007.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e1" e2="DDI-PubMed.24219007.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e1" e2="DDI-PubMed.24219007.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e1" e2="DDI-PubMed.24219007.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e2" e2="DDI-PubMed.24219007.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e2" e2="DDI-PubMed.24219007.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e2" e2="DDI-PubMed.24219007.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e2" e2="DDI-PubMed.24219007.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e3" e2="DDI-PubMed.24219007.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e3" e2="DDI-PubMed.24219007.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e3" e2="DDI-PubMed.24219007.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e4" e2="DDI-PubMed.24219007.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24219007.s8.e4" e2="DDI-PubMed.24219007.s8.e5" /></sentence><sentence text=" Conversely, a population PK analysis of combined data from phase I, II and III studies showed that none of the coadministered AEDs affected retigabine clearance apart from lamotrigine which lowered retigabine clearance by 6"><entity charOffset="141-151" id="DDI-PubMed.24219007.s9.e0" text="retigabine" /><entity charOffset="173-184" id="DDI-PubMed.24219007.s9.e1" text="lamotrigine" /><entity charOffset="199-209" id="DDI-PubMed.24219007.s9.e2" text="retigabine" /><pair ddi="false" e1="DDI-PubMed.24219007.s9.e0" e2="DDI-PubMed.24219007.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24219007.s9.e0" e2="DDI-PubMed.24219007.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24219007.s9.e0" e2="DDI-PubMed.24219007.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24219007.s9.e1" e2="DDI-PubMed.24219007.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24219007.s9.e1" e2="DDI-PubMed.24219007.s9.e2" /></sentence><sentence text="7%" /><sentence text="" /><sentence text="Retigabine is not metabolized by CYP isozymes and does not induce or inhibit these isozymes at clinically relevant concentrations"><entity charOffset="0-10" id="DDI-PubMed.24219007.s12.e0" text="Retigabine" /></sentence><sentence text=" Therefore, retigabine is associated with a low potential for PK interactions with other drugs via CYP450"><entity charOffset="12-22" id="DDI-PubMed.24219007.s13.e0" text="retigabine" /></sentence><sentence text=" Overall, there was little or no potential for retigabine to interact with other available AEDs"><entity charOffset="47-57" id="DDI-PubMed.24219007.s14.e0" text="retigabine" /></sentence><sentence text=" Although some PK interactions were observed with lamotrigine, these are unlikely to be clinically relevant"><entity charOffset="50-61" id="DDI-PubMed.24219007.s15.e0" text="lamotrigine" /></sentence><sentence text="" /></document>